Patents by Inventor John R. Ticehurst

John R. Ticehurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric hepatitis A vaccine
    Patent number: 5837260
    Abstract: A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: The United of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey I. Cohen, Robert H. Purcell, Stephen M. Feinstone, John R. Ticehurst
  • Methods of detecting hepatitis A virus
    Patent number: 5516630
    Abstract: Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimetic plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: May 14, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: John R. Ticehurst, David Baltimore, Stephen M. Feinstone, Robert H. Purcell, Vincent R. Racaniello, Bahige M. Baroudy
  • cDNA encoding attenuated cell culture adapted hepatitis A virus genome
    Patent number: 5478746
    Abstract: A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.
    Type: Grant
    Filed: September 13, 1993
    Date of Patent: December 26, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey I. Cohen, Robert H. Purcell, Stphen M. Feinstone, John R. Ticehurst
  • Vaccine against hepatitis A virus
    Patent number: 4894228
    Abstract: The present invention provides an attenuated hepatitis A virus useful as a vaccine.
    Type: Grant
    Filed: July 12, 1988
    Date of Patent: January 16, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert H. Purcell, John R. Ticehurst, Jeffrey I. Cohen, Suzanne U. Emerson, Stephan M. Feinstone, Richard J. Daemer, Ian D. Gust
  • Vaccine against hepatitis A virus
    Patent number: RE37381
    Abstract: The present invention provides an attenuated hepatitis A virus useful as a vaccine.
    Type: Grant
    Filed: September 6, 1995
    Date of Patent: September 18, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert H. Purcell, John R. Ticehurst, Jeffrey I. Cohen, Suzanne U. Emerson, Stephen M. Feinstone, Richard J. Daemer, Ian D. Gust